Insulin Pumps Market

A pump is bought once but its infusion sets are bought every three days, and that consumable stream is worth more over a decade than the device itself. On 18 February 2026 Insulet, maker of the disposable Omnipod patch pump, reported 2025 revenue of USD 2.71 billion, up 30.7%, in its fourth-quarter and full-year results, the clearest sign of where pump spending is moving. Douglas Insights values the insulin pumps market at USD 7.59 billion in 2025 and expects USD 17.9 billion by 2035, compounding at 8.94%. The estimate is built from the bottom up: roughly 2.2 million people using insulin pumps in 2025 across tubeless patch pumps, tubed durable pumps, infusion sets and reservoirs, and automated insulin delivery algorithms and software, at an average annual revenue of USD 3,450 per user covering the amortised pump and consumables, triangulated against diabetes prevalence, pump adoption data and manufacturer disclosures. Users grow 9.6% a year as automated insulin delivery improves outcomes and use extends to type 2 diabetes, while revenue per user eases 0.6% a year as competition and pharmacy channels spread. Continuous glucose monitoring sensors, covered in our separate sensor coverage, and hospital infusion pumps, covered in our portable IV infusion pump market report, are excluded. This study sits within our diabetes devices coverage and follows the published Douglas Insights methodology.

How did pumps become an artificial pancreas?

By connecting to continuous glucose monitors and letting software adjust insulin automatically, which has changed insulin pumps from programmable syringes into systems that partly manage diabetes on their own. That shift is why AID algorithms and software grow 11.05% a year in our model and why automated delivery now drives most pump adoption.

People with type 1 diabetes must replace the insulin their pancreas no longer makes, traditionally through several daily injections or a pump that delivers insulin continuously according to settings the user programs. Continuous glucose monitors now measure glucose every few minutes, and automated insulin delivery systems, often called hybrid closed loop systems, use algorithms to raise or lower insulin delivery in response to those readings, preventing many highs and lows without user action. Users still announce meals in most systems, which is why they are called hybrid, but the improvement in time spent in a healthy glucose range and the reduction in dangerous overnight lows have been substantial. As a result, automated insulin delivery has become the standard of care recommended by many diabetes guidelines, driving pump adoption. The exclusive chapter of this report tracks automated insulin delivery adoption by region and diabetes type, since it is the main driver of growth.

What is inside an insulin pump bill: pods, tubed pumps, infusion sets or software?

An insulin pump bill covers four things worth USD 7.59 billion together in 2025: tubeless patch pumps, tubed durable pumps, the infusion sets and reservoirs that durable pumps consume, and automated insulin delivery (AID) algorithms and software. Glucose sensors, insulin and pens are billed separately and sit outside this study, valued at manufacturer realised revenue.

This study covers insulin pumps and their dedicated consumables. Tubeless patch pumps cover pumps worn directly on the body that deliver insulin without tubing and are replaced every few days, the largest and fastest growing category. Tubed durable pumps cover pumps carried on a belt or in a pocket, connected by tubing to an infusion site, and used for several years. Infusion sets and reservoirs cover the disposable tubing, cannulas and insulin reservoirs used with durable pumps. Automated insulin delivery algorithms and software cover control software, apps and subscriptions associated with automated delivery. Continuous glucose monitoring sensors, covered in our separate glucose sensor coverage, insulin itself, insulin pens and syringes, and hospital infusion pumps, covered in our separate infusion pump coverage, sit outside the boundary. Value is measured at manufacturer realised revenue.

Will type 2 diabetes open a much larger market?

Potentially yes, because far more people have type 2 diabetes than type 1, and many of them use insulin, but uptake among them has so far been limited. Insulin pumps have mainly served people with type 1 diabetes, a relatively small population. Many people with type 2 diabetes eventually need insulin, often injected several times a day, and some of them could benefit from pumps, particularly simple patch pumps and automated systems that reduce the burden of multiple daily injections. Regulators have begun to clear automated insulin delivery systems for type 2 diabetes, and simple patch pumps designed for type 2 are available. However, cost, reimbursement and the effectiveness of newer drugs such as GLP-1 medicines, which reduce many people’s need for insulin, may limit the expansion. The model treats type 2 as a growing source of users, contributing meaningfully to volume, with the upside scenario capturing faster adoption.

Why are people with diabetes switching from injections to insulin pumps?

Pump users grow 9.6% a year in our model, from about 2.2 million in 2025 to about 5.5 million in 2035, because automated insulin delivery makes a pump do part of the daily work that injections leave to the patient. Tubeless pods, type 2 use and pharmacy access add to that pull, and each shows up in 2025 company results.

Automated insulin delivery is the first driver. A pump linked to a continuous glucose monitor raises and lowers insulin every few minutes, and that is now the reason most people start pump therapy rather than a feature they add later. AID algorithms and software are the second-fastest category in our model at 11.05% a year, from USD 607.2 million in 2025 to USD 1.73 billion in 2035, and Insulet reported U.S. Omnipod revenue of USD 1.92 billion for 2025, up 27.2%, as automated systems pulled new users onto pods.

Tubeless convenience is the second driver. A pod stuck to the skin removes the tubing that put many people off pumps, and the 2025 results show the gap: Insulet’s total revenue rose 30.7% while Tandem Diabetes Care, whose range is mainly tubed, grew worldwide sales 8% to USD 1.01 billion, according to its results of 19 February 2026. In our model tubeless patch pumps grow 12.15% a year against 5.08% for tubed durable pumps.

Type 2 expansion is the third driver, and the largest source of upside. People with type 2 diabetes who use insulin far outnumber people with type 1, and simple patch pumps and automated systems cleared for type 2 reduce the burden of several daily injections. Our type-2-expansion case lifts user growth from 9.6% to 12.0% a year and takes the 2035 market past USD 24.5 billion, against USD 17.9 billion in the base case.

Access outside the United States is the fourth driver. Insulet’s international Omnipod revenue rose 44.1% to USD 754.3 million in 2025 after Omnipod 5 launched in nine new markets, and Tandem’s sales outside the U.S. rose 15% to USD 307.8 million. Reimbursement for automated systems in Europe and pharmacy-channel distribution in the U.S. are why Europe grows 9.2% a year and Asia Pacific 12.0% in our model, both faster than North America.

What holds back insulin pumps: cost, GLP-1 drugs or safety recalls?

Cost is the largest barrier: insulin pumps average USD 3,450 per user a year in 2025, and coverage decides who can pay it. GLP-1 medicines and device safety are the other two restraints, and together they explain why revenue per user eases 0.6% a year while users grow.

Cost and reimbursement are the first restraint. A tubed pump costs several thousand dollars upfront and its supplies are bought every few days, so in countries where insurers or health systems do not reimburse automated systems, pump use stays low. Africa, at USD 37.9 million in 2025, and Latin America, at USD 113.9 million, together hold about 2% of world value for this reason.

GLP-1 medicines are the second restraint. Drugs that improve glucose control and reduce weight can delay or reduce insulin needs for many people with type 2 diabetes, which is the pool the industry counts on for growth; the insulin side of that shift is sized in our Insulin Drug Market report. Our GLP-1-headwind case cuts user growth to 6.6% a year and revenue per user by 1.6% a year, leaving the market near USD 12.2 billion in 2035, USD 5.6 billion below the base case.

Complexity and safety are the third restraint. Pumps need training and can fail to deliver insulin when a cannula kinks or a pod detaches, and recalls have affected some products, so new users and prescribers move cautiously.

Do patch pods, tubed pumps, infusion sets or AID software earn the most?

Tubeless patch pumps earn the most, 42% of 2025 insulin pump value or USD 3.19 billion, and grow fastest at 12.15% a year to USD 10.03 billion, more than the whole market was worth in 2025. Tubed durable pumps follow at 30%, infusion sets and reservoirs at 20% and AID algorithms and software at 8%.

Tubeless patch pumps, USD 3.19 billion, lead because the pod is both pump and disposable, so every user buys a new one every few days; Insulet’s Omnipod revenue of USD 2.67 billion in 2025 is about 84% of the category. Tubed durable pumps, USD 2.28 billion, hold 30% on the longest-established automated systems from Medtronic’s MiniMed and Tandem, and grow 5.08% a year because each pump lasts several years. Infusion sets and reservoirs, USD 1.52 billion, are 20% of value and the most dependable recurring revenue in the market, yet they grow slowest at 4.58% because they are tied to tubed pumps only. AID algorithms and software, USD 607.2 million and 8% of value, grow 11.05% a year as control apps and subscriptions spread with every automated system sold. Each category is modelled through 2035 by region.

Which insulin pumps segment grows fastest?

Tubeless patch pumps grow fastest, at 12.15% a year against the market’s 8.94%, from USD 3.19 billion to USD 10.03 billion, and they take their growth from two places at once. They win new users, because a pump with no tubing is the version people who refused pump therapy will accept, and they convert the consumable stream, because a patch pump is itself the disposable: there is no separate infusion set to buy. That is why infusion sets and reservoirs are the slowest category at 4.58% even though they are the most reliably recurring revenue in the market, and why tubed durable pumps grow only 5.08% despite carrying the longest-established automated systems. Automated insulin delivery algorithms and software grow 11.05% on their own, but most of that value is increasingly sold inside a pump rather than beside it, which caps how much of it this line ever shows.

Which regions spend most on insulin pumps, and where does use grow fastest?

North America spends most, 58% of 2025 insulin pump value or USD 4.40 billion, growing 8.07% a year to USD 9.56 billion by 2035. Europe holds 28% and grows 9.2%, while Asia Pacific, at 10% of value, grows fastest at 12.0% a year from low adoption in large populations.

North America leads because U.S. insurers and pharmacy benefits cover automated systems widely and the main pump makers sell there first. Insulet’s U.S. revenue of USD 1.92 billion alone equals about 44% of the North American total, and Tandem sold USD 706.9 million in the U.S. Growth runs below the world rate because pump adoption is already high, so more of the new users must come from type 2.

Europe, USD 2.13 billion in 2025, reaches USD 5.12 billion by 2035 at 9.2% a year as national health systems add reimbursement for automated insulin delivery. Under the EU Medical Device Regulation (EU) 2017/745, every pump, pod and algorithm needs certification before sale, which slows launches but makes reimbursement decisions easier once a product is in.

Asia Pacific, USD 759.0 million in 2025, triples to USD 2.36 billion by 2035, the fastest of any region at 12.0% a year, on large insulin-using populations in China, India and Japan and regional pump makers in China and Korea. The Middle East contributes USD 151.8 million at 11.0%, Latin America USD 113.9 million at 10.4% and Africa USD 37.9 million at 9.6%. Six regional models sum to the global figure, with country tables in the Excel model.

Which companies dominate insulin pumps, and how much of the market does Insulet hold?

Insulet leads insulin pumps with about 35.2% of 2025 value, from USD 2.67 billion of Omnipod revenue against our USD 7.59 billion market, and Tandem Diabetes Care follows at about 13.4%; the two together hold 48.6%. The basis is each company’s disclosed 2025 revenue, a Douglas Insights calculation.

Insulet’s lead rests on the pod: it sells a disposable device every few days rather than a durable pump every few years, and its results of 18 February 2026 showed revenue up 30.7% with Omnipod 5 launched in nine new markets during 2025. Tandem’s position rests on tubed pumps and its Control-IQ+ algorithm, and in the fourth quarter of 2025 it began a global rollout of t:slim X2 integration with Abbott’s FreeStyle Libre 3 Plus sensor.

Medtronic separated its diabetes business as MiniMed, which began trading on Nasdaq on 6 March 2026 after raising about USD 560 million, HPN reported. MiniMed sells both tubed pumps and glucose sensors, and its pump revenue is not disclosed separately, so no share is shown for it here. Beta Bionics, Roche and Ypsomed offer pumps and automated systems, Chinese and Korean makers supply regional markets, and pump makers partner with sensor makers such as Dexcom and Abbott, whose devices are sized in our Continuous Glucose Monitoring Sensor Manufacturing Market report.

How much does a year on an insulin pump cost, pod or tubed?

Average revenue is USD 3,450 per user per year in 2025, combining pump hardware spread over its life with consumables, and Douglas Insights expects it to ease 0.6% a year as pharmacy channels and competition spread. A patch pump user pays as they go; a tubed pump user pays upfront and then for sets.

Durable pumps cost several thousand dollars upfront and last several years, with infusion sets and reservoirs purchased regularly, while patch pumps are bought as disposable units every few days, making their cost ongoing rather than upfront. Reimbursement and pharmacy benefit coverage strongly affect prices, and competition and pharmacy channels ease average revenue per user slightly. The pricing chapter publishes price bands by category.

If GLP-1 drugs cut insulin use, how far apart are the 2035 insulin pump cases?

Insulin pumps reach USD 17.9 billion in 2035 in the base case, inside a range of USD 12.2 billion to USD 24.5 billion. How many people with type 2 diabetes move to pumps, and how far GLP-1 drugs cut their insulin needs, decide where in that range the market lands.

The base case carries 9.6% growth in users and a 0.6% annual decline in revenue per user for an 8.94% revenue CAGR. The GLP-1-headwind scenario, in which newer medicines limit insulin use and reimbursement tightens, sets the legs at 6.6% and minus 1.6%, landing near USD 12.2 billion. The type-2-expansion scenario, in which automated insulin delivery spreads widely among people with type 2 diabetes, sets them at 12.0% and 0.4%, carrying the market past USD 24.5 billion. Insulet’s 30.7% revenue growth in 2025 shows the faster path is possible for the leader; Tandem’s 8% shows how far a tubed range can trail it. Each 1-point change in user growth moves the 2035 figure by roughly USD 1.64 billion.

Our 8.94% base rate sits in the middle of the 6% to 14% range of published insulin pump forecasts, because we count pumps, consumables and AID software but not glucose sensors or insulin, which some wider studies include.

Which device, reimbursement and cybersecurity rules decide who can use an insulin pump?

Three layers of rules decide insulin pump use: device certification, reimbursement and cybersecurity. Reimbursement matters most for the numbers, because coverage decisions explain why North America holds 58% of 2025 value while Africa and Latin America together hold about 2%.

Medical device regulation comes first: insulin pumps and automated delivery algorithms are regulated medical devices, and interoperability pathways allow compatible pumps, sensors and algorithms to be combined. Reimbursement is second: coverage decisions, including coverage through pharmacy benefits, largely determine adoption. Cybersecurity and data rules are third: connected pumps must meet cybersecurity requirements and health data protections. The regulatory chapter maps these requirements by jurisdiction.

Will fully automated systems remove the need to count meals?

Fully closed loop systems that need no meal announcements are the next goal, and some systems already reduce the burden by adapting automatically to meals, but insulin’s slow action limits how well any system can respond to eating without warning.

Faster acting insulins, better algorithms and combinations with other hormones are being developed to move closer to a fully automatic artificial pancreas. The closer systems come to full automation, the more attractive pumps become compared with injections, particularly for children and people who struggle with daily management. The model treats continued algorithm improvement as supporting adoption throughout the forecast.

Douglas Exclusive: the automated insulin delivery adoption tracker

The automated insulin delivery adoption tracker is a Douglas Insights model, an estimate rather than an official register, built from 6 regional user models and 3 published sources: the 2025 results of Insulet and Tandem Diabetes Care, used to check the patch and tubed totals, and Regulation (EU) 2017/745. Douglas Insights counts 6 regional rows in it. It tracks, by region and diabetes type, insulin using populations, pump penetration, automated insulin delivery adoption, reimbursement status and device mix, converting diabetes epidemiology into pump users and revenue by category and region. Licence holders receive it as a maintained tab in the Excel model.

Methodology and receipts

The model is built bottom-up from users: type 1 and insulin using type 2 populations by region, pump penetration and automated delivery adoption, device and consumables revenue per user, and realised revenue from manufacturer disclosures, with glucose sensors, insulin, pens and syringes, and hospital infusion pumps excluded. Every figure carries a numbered source and a confidence grade in the fact sheet above, and the working model ships with every licence. The next scheduled review of this study is September 2027.

Two cross-checks support the base. Insulet’s 2025 Omnipod revenue, USD 2.67 billion, is 84% of our USD 3.19 billion tubeless patch pump category, leaving room for other pod makers and regional brands; Tandem’s USD 1.01 billion, pumps and supplies together, is 27% of our USD 3.80 billion tubed pump plus infusion set total, consistent with MiniMed and others holding the rest.

How this report was made: AI tools helped draft the text and automated checks test every figure for arithmetic, units and consistency with the data table; the Douglas Insights research desk chose the sources, built the model and approved the page. Our editorial standards explain the process.

Sources

1. Insulet / Business Wire Insulet Reports Fourth Quarter and Full Year 2025 Results (2026)
2. Tandem Diabetes Care / SEC Tandem Diabetes Care fourth quarter and full year 2025 results (Form 8-K exhibit) (2026)
3. HPN Medtronic spinoff MiniMed raises USD 560M in Nasdaq IPO (2026)
4. EUR-Lex Regulation (EU) 2017/745 on medical devices (2017)